132 related articles for article (PubMed ID: 28210148)
1. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
2. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Tanaka M; Siemann DW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32660000
[TBL] [Abstract][Full Text] [Related]
3. Implications of the Receptor Tyrosine Kinase Axl in Gastric Cancer Progression.
He L; Lei Y; Hou J; Wu J; Lv G
Onco Targets Ther; 2020; 13():5901-5911. PubMed ID: 32606800
[TBL] [Abstract][Full Text] [Related]
4. Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
Zhang G; Wang M; Zhao H; Cui W
Oncol Lett; 2018 Mar; 15(3):2726-2734. PubMed ID: 29434997
[TBL] [Abstract][Full Text] [Related]
5. Immune Evasion Mechanism and AXL.
Son HY; Jeong HK
Front Oncol; 2021; 11():756225. PubMed ID: 34778071
[TBL] [Abstract][Full Text] [Related]
6. Engineered AXL
Duan Y; Hu B; Qiao C; Luo L; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Oncol Lett; 2019 Jun; 17(6):5784-5792. PubMed ID: 31186805
[TBL] [Abstract][Full Text] [Related]
7. Gas6/AXL pathway: immunological landscape and therapeutic potential.
Zhai X; Pu D; Wang R; Zhang J; Lin Y; Wang Y; Zhai N; Peng X; Zhou Q; Li L
Front Oncol; 2023; 13():1121130. PubMed ID: 37265798
[TBL] [Abstract][Full Text] [Related]
8. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
Yan S; Vandewalle N; De Beule N; Faict S; Maes K; De Bruyne E; Menu E; Vanderkerken K; De Veirman K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694201
[TBL] [Abstract][Full Text] [Related]
9. The Receptor Tyrosine Kinase AXL in Cancer Progression.
Rankin EB; Giaccia AJ
Cancers (Basel); 2016 Nov; 8(11):. PubMed ID: 27834845
[TBL] [Abstract][Full Text] [Related]
10. The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Sang YB; Kim JH; Kim CG; Hong MH; Kim HR; Cho BC; Lim SM
Front Oncol; 2022; 12():811247. PubMed ID: 35311091
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review.
Zhang S; Xu XS; Yang JX; Guo JH; Chao TF; Tong Y
Onco Targets Ther; 2018; 11():509-519. PubMed ID: 29416351
[TBL] [Abstract][Full Text] [Related]
12. Targeting AXL in NSCLC.
Zaman A; Bivona TG
Lung Cancer (Auckl); 2021; 12():67-79. PubMed ID: 34408519
[TBL] [Abstract][Full Text] [Related]
13. Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells.
Chang H; An R; Li X; Lang X; Feng J; Lv M
Oncol Lett; 2021 Nov; 22(5):749. PubMed ID: 34539853
[TBL] [Abstract][Full Text] [Related]
14. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.
Saab S; Chang OS; Nagaoka K; Hung MC; Yamaguchi H
Am J Cancer Res; 2019; 9(12):2719-2729. PubMed ID: 31911857
[TBL] [Abstract][Full Text] [Related]
15. The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation.
Melchionna R; Spada S; Di Modugno F; D'Andrea D; Di Carlo A; Panetta M; Mileo AM; Sperduti I; Antoniani B; Gallo E; Lawlor RT; Piemonti L; Visca P; Milella M; Grazi GL; Facciolo F; Chen E; Scarpa A; Nisticò P
EMBO Rep; 2020 Nov; 21(11):e50078. PubMed ID: 32909687
[TBL] [Abstract][Full Text] [Related]
16. AXL as a Target in Breast Cancer Therapy.
Colavito SA
J Oncol; 2020; 2020():5291952. PubMed ID: 32148495
[TBL] [Abstract][Full Text] [Related]
17. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.
Lee HJ; Jeng YM; Chen YL; Chung L; Yuan RH
Carcinogenesis; 2014 Apr; 35(4):769-75. PubMed ID: 24233839
[TBL] [Abstract][Full Text] [Related]
18. PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma.
Hedrich V; Breitenecker K; Ortmayr G; Pupp F; Huber H; Chen D; Sahoo S; Jolly MK; Mikulits W
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173882
[TBL] [Abstract][Full Text] [Related]
19. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.
Wium M; Ajayi-Smith AF; Paccez JD; Zerbini LF
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806258
[TBL] [Abstract][Full Text] [Related]
20. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.
Nakamichi S; Seike M; Miyanaga A; Chiba M; Zou F; Takahashi A; Ishikawa A; Kunugi S; Noro R; Kubota K; Gemma A
Oncotarget; 2018 Jun; 9(43):27242-27255. PubMed ID: 29930762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
